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Abstract
Objectives: The aim of this study was to identify predictors for longterm survival following pancreati-
coduodenectomy (PD) for pancreatic and other periampullary adenocarcinomas.
Methods: Clinicopathological factors were compared between short-term (<5 years) and longterm (5
years) survival groups. Rates of actual 5-year and actuarial 10-year survival were determined.
Results: There were 109 (21.8%) longterm survivors among a sample of 501 patients. Patients with
ampullary adenocarcinoma represented 76.1% of the longterm survivors. Favourable factors for longterm
survival included female gender, lack of jaundice, lower blood loss, classical PD, absence of postopera-
tive bleeding or intra-abdominal abscess, non-pancreatic primary cancer, earlier tumour stage, smaller
tumour size (2 cm), curative resection, negative lymph node involvement, well-differentiated tumours,
and absence of perineural invasion. Independent factors associated with longterm survival were diagno-
sis of primary tumour, jaundice, intra-abdominal abscess, tumour stage, tumour size, radicality, lymph
node status and cell differentiation. The prognosis was best for ampullary adenocarcinoma, for which the
rate of actual 5-year survival was 32.8%, and poorest for pancreatic head adenocarcinoma, for which
actual 5-year survival was only 6.5%.
Conclusions: The majority of longterm survivors after PD for periampullary adenocarcinomas are
patients with ampullary adenocarcinoma. The longterm prognosis in pancreatic head adenocarcinoma
remains dismal.
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Introduction
Pancreaticoduodenectomy (PD) is the treatment of choice for
periampullary adenocarcinomas. An increase in experience and
advances in perioperative care have reduced perioperative mor-
tality following PD to <5% in high-volume centres.1–7 Only
10–15% of patients presenting with pancreatic adenocarcinoma
are technically resectable8,9 and for those who do undergo resec-
tion, the prognosis remains poor, with median survival of 11–19
months.1,8–26 Even the addition of adjuvant therapies has resulted
in only modest improvements in survival. Several studies have
reported on actual longterm survival beyond 5 years in patients
subjected to resection for pancreatic or other periampullary
cancers.1,10–19,26–29 Clinical factors, such as lymph node metastasis,
tumour size and resection margin, have been comprehensively
studied with respect to determining short-term survival after
PD for pancreatic and other periampullary cancers.11,13,19,27,30
However, prognostic factors that may predict longterm survival
are poorly understood.
The purpose of this study was to identify the predictors of
longterm survival (5 years) in patients with pancreatic and
other periampullary adenocarcinomas after PD. In addition,
actual 5-year and actuarial 10-year survival rates in all patients
with periampullary adenocarcinomas after PD were determined.
Materials and methods
Data for patients with pancreatic or other periampullary adeno-
carcinomas who underwent PD between 1974 and 2006 were*These authors contributed equally to this paper.
DOI:10.1111/hpb.12071 HPB
HPB 2013, 15, 951–957 © 2013 International Hepato-Pancreato-Biliary Association
retrieved from a prospectively collected database for pancreatic
surgery. Data for patients with other malignancies, such as intra-
ductal papillary mucinous neoplasms, mucinous cystadenocarci-
noma, acinar cell carcinoma, solid pseudopapillary neoplasms
and neuroendocrine carcinoma, were excluded from the analysis.
The number of surgeons who performed at least one PD
during the study period was 26. Five surgeons each performed
15 PDs and 65.3% of all PDs were performed by two high-
volume surgeons, each of whom performed 15 PDs per year. A
standard resection without extensive retroperitoneal lymph node
dissection was performed. The decision on whether the proce-
dure should consist of a classical PD or a pylorus-preserving
resection was left to the discretion of the operating surgeon. A
pancreaticogastrostomy or pancreaticojejunostomy was used for
pancreaticoenteric reconstruction. Curative resection was defined
as a PD without evidence of any residual cancer at the resection
margins, including the pancreatic neck and distal common bile
duct (CBD) cut-ends, retroperitoneal margin, and superior
mesenteric and portal vein grooves. A palliative resection was
defined as including either gross or microscopic evidence of
cancer at the resection margin. The definition of primary tumour
origin was mainly based on pathological findings; however, image
studies and gross findings were also taken into consideration for
primary tumour origin when pathological determination was
unclear. Postoperatively, patients were followed at 6-month inter-
vals for5 years or until death. Patients with operative mortality
were included in this study. Patient who died from causes other
than cancer were also included, but their data were censored for
survival analysis.
Based on survival time, patients were stratified into two groups
consisting of, respectively, short-term (<5 years) and longterm
(5 years) survivors. Patient demographics, the pathological
characteristics of tumours, surgical factors and risk factors were
compared between these two groups. Actual 5-year survival in all
Table 1 Demographics of patients with periampullary adenocarcinomas submitted to pancreaticoduodenectomy
Variable Total Survival
<5 years
Survival
5 years
P-value
Patients, n (%) 501 (100%) 392 (78.2%) 109 (21.8%)
Gender, n (%) <0.001
Male 368 (73.5%) 303 (77.3%) 65 (59.6%)
Female 133 (26.5%) 89 (22.7%) 44 (40.4%)
Age, years 0.201
Median (range) 67 (25–89) 67 (25–89) 65 (34–89)
Mean  SD 64.6  11.4 65.0  11.4 63.4  11.5
Diagnosis of primary tumour, n (%) <0.001
Pancreatic head 169 158 (93.5%) 11 (6.5%)
Ampullary 253 170 (67.2%) 83 (32.8%)
Distal CBD 52 42 (80.8%) 10 (19.2%)
Duodenal 27 22 (81.5%) 5 (18.5%)
Duration of symptoms, months, median (range) 1 (0–120) 1 (0–120) 1 (0–24) 0.514
Symptoms, n (%)
No symptoms 9 (1.8%) 7 (1.8%) 2 (1.8%) 1.000
Jaundice 393 (78.4%) 320 (81.6%) 73 (67.3%) 0.002
Epigastric pain 219 (43.7%) 165 (42.1%) 54 (49.5%) 0.190
Body weight loss 177 (35.3%) 136 (34.7%) 41 (37.6%) 0.573
Nausea/vomiting 56 (11.2%) 46 (11.2%) 10 (9.3%) 0.606
Diabetes mellitus 77 (8.3%) 68 (17.3%) 9 (8.3%) 0.023
Serum CA 19-9, U/ml, median (range) 73 (0–18 545) 92 (0–18 545) 36 (2–12 000) 0.207
Serum CEA, ng/ml, median (range) 4 (1–143) 4 (1–143) 4 (1–19) 0.205
Chemotherapy, n (%) 0.204
No 275 (56.8%) 219 (57.9%) 56 (52.8%)
Yes 209 (43.2%) 159 (42.1%) 50 (47.2%)
Radiotherapy, n (%) 0.158
No 278 (57.6%) 222 (58.9%) 56 (52.8%)
Yes 205 (42.4%) 155 (41.1%) 50 (47.2%)
SD, standard deviation; CBD, common bile duct; CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen.
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patients with pancreatic and other periampullary adenocarcino-
mas after PD was determined. For patients who survived 5 years,
actuarial 10-year survival was calculated.
pasw Statistics Version 18 (SPSS, Inc., Chicago, IL, USA) was
used for all statistical analyses. All continuous data were
expressed as the mean  standard deviation (SD) or as the
median (range), as appropriate. Comparisons of data between
the primary groups were performed using a Student’s t-test or
Wilcoxon rank sum test, as appropriate, for continuous variables.
Categorical variables were compared using a chi-squared or Fish-
er’s exact test. P-values were derived from two-tailed tests. Sur-
vival was calculated following PD. Using the binary logistic
regression model for all factors with a P-value of <0.2 after uni-
variate analysis, multivariate analysis was performed to identify
independent predictors of longterm survival of 5 years after
PD. Cumulative survival was estimated using the Kaplan–Meier
method and differences between subgroups were determined
using a log-rank test. A P-value of <0.05 was considered to indi-
cate statistical significance.
Results
A total of 501 patients with periampullary adenocarcinomas
underwent PD during the study period. Of these, 109 (21.8%)
were longterm survivors (5 years) and 392 (78.2%) were short-
term survivors (<5 years). Among the 109 longterm survivors,
83 (76.1%) were operated for ampullary adenocarcinoma, 11
(10.1%) for pancreatic head adenocarcinoma, 10 (9.2%) for distal
CBD adenocarcinoma, and five (4.6%) for duodenal adenocarci-
noma. Univariate analyses of various factors associated with sur-
vival status are shown in Tables 1–3. Following multivariate
analysis with a binary logistic regression model, diagnosis of the
primary tumour, jaundice, intra-abdominal abscess, tumour
stage, tumour size, radicality, lymph node status and cell differen-
tiation were found to be independent predictors of longterm sur-
vival after PD (Table 4).
Of the 392 (78.2%) patients who died within 5 years of PD,
378 (96.4%) died as a result of recurrent disease. Fourteen
(3.6%) patients were lost to follow-up. Patients with ampullary
adenocarcinoma (32.8%) showed the highest actual 5-year sur-
vival rate, followed by those with distal CBD adenocarcinoma
(19.2%) and duodenal adenocarcinoma (18.5%). The lowest
actual 5-year survival was found in patients with pancreatic
head adenocarcinoma (6.5%). Overall actual 5-year survival in
patients with periampullary adenocarcinomas was 21.8% (109
patients were alive). The median length of survival was 21.0
months across all patients, 13.7 months in patients with pancre-
atic head adenocarcinoma, 28.9 months in those with ampullary
Table 2 Surgical factors and risks in pancreaticoduodenectomy (PD)
Total Survival
<5 years
Survival
5 years
P-value
Operation time, h 0.161
Median (range) 7.5 (3.5–16) 7.5 (3.5–16) 8.5 (4.0–14)
Mean  SD 8.0  2.3 7.8  2.4 8.3  2.0
Surgeon volume, n (%) 0.294
High (15 PD/year) 406 (81.2%) 315 (80.6%) 91 (83.5%)
Low (<15 PD/year) 94 (8.8%) 76 (19.4%) 18 (16.5%)
Blood loss, ml 0.005
Median (range) 800 (50–5250) 800 (50–5250) 575 (100–2950)
Mean  SD 903  618 954  639 709  487
Pylorus-preserving PD, n (%) 0.048
No 288 (57.5%) 216 (55.1%) 72 (66.1%)
Yes 213 (42.5%) 176 (44.9%) 37 (33.9%)
Postoperative hospital stay, days, median (range) 26.0 (1–383) 26.0 (1–383) 26.5 (5–87) 0.531
Surgical morbidity, overall, n (%) 225 (44.9%) 174 (44.4%) 11 (10.1%) 0.665
Pancreatic leakage, n (%) 55 (11.10%) 44 (11.2%) 11 (10.1%) 0.863
Gastric atonia, n (%) 52 (10.3%) 40 (10.2%) 12 (11.0%) 0.859
Post-PD bleeding, n (%) 53 (10.6%) 49 (12.5%) 4 (3.7%) 0.007
Intraluminal post-PD bleeding, n (%) 31 (6.2%) 30 (7.7%) 1 (0.9%) 0.006
Extraluminal post-PD bleeding, n (%) 32 (6.4%) 28 (7.1%) 4 (3.7%) 0.267
Intra-abdominal abscess, n (%) 55 (11.0%) 35 (8.9%) 20 (18.3%) 0.009
Wound infection, n (%) 54 (10.8%) 39 (9.9%) 15 (13.8%) 0.294
SD, standard deviation.
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adenocarcinoma, 24.4 months in those with distal CBD adeno-
carcinoma, and 21.7 months in those with duodenal adenocar-
cinoma. Figure 1 shows actuarial survival curves for individual
histological subtypes following PD.
Of the 109 actual 5-year survivors, 56 (51.4%) were alive at 10
years. A total of 24 (22.0%) 5-year survivors had died, 22 of them
as a result of the disease process. Actuarial 10-year survival in
actual 5-year longterm survivors according to histological subtype
is shown in Table 5.
Discussion
Pancreaticoduodenectomy was previously abandoned by nihilistic
surgeons confronted with patients diagnosed with periampullary
adenocarcinomas because of the high surgical risk associated with
the procedure and dismal survival outcomes, especially as pancre-
atic primary cancers were regarded as lethal.10,17,31 However,
decreasing perioperative mortality and encouraging improve-
ments in survival since the 1990s have allowed PD to become the
standard of care for patients with resectable periampullary
adenocarcinomas.8,10–17 Prognoses in periampullary adenocarci-
nomas vary and depend on the origin of the primary tumour.
Patients with pancreatic head adenocarcinoma have the worst
prognosis, with 5-year survival of 5–20% after resection.9,11,19–32
Prognosis is better in ampullary adenocarcinoma, in which 5-year
survival is 30–40%,10,23,33–35 and duodenal adenocarcinoma, in
which 5-year survival is 50–65%.10,23,36 Furthermore, 5-year sur-
vival in distal CBD adenocarcinoma is approximately 20–30%.10,33
Table 3 Pathological parameters in patients with periampullary adenocarcinomas undergoing pancreaticoduodenectomy
Total Survival
<5 years
Survival
5 years
P-value
Stage, n (%) 0.003
0 15 (3.0%) 10 (2.6%) 5 (4.6%)
I 84 (16.8%) 56 (14.3%) 28 (25.7%)
II 279 (55.7%) 217 (55.4%) 62 (56.9%)
III 92 (18.4%) 83 (21.2%) 9 (8.3%)
IV 31 (6.2%) 26 (6.6%) 5 (4.6%)
Stage, n (%) 0.001
0 + I + II 387 (75.4%) 283 (72.2%) 95 (87.2%)
III + IV 123 (24.6%) 109 (27.8%) 14 (12.8%)
Tumour size, n (%) 0.006
2 cm 218 (43.5%) 158 (40.3%) 60 (55.0%)
>2 cm 283 (56.5%) 234 (59.7%) 49 (45.0%)
Tumour size, cm 0.020
Median (range) 2.5 (0.4–15) 2.5 (0.5–15) 2.0 (0.4–8)
Mean  SD 2.8  1.6 2.9  1.6 2.5  1.4
Radicality, n (%) <0.001
Curative 422 (84.2%) 317 (80.9%) 105 (96.3%)
Palliative 79 (15.8%) 75 (19.1%) 4 (3.7%)
Lymph node involvement, n (%) <0.001
Negative 302 (60.7%) 211 (53.8%) 93 (85.3%)
Positive 197 (39.3%) 181 (46.2%) 16 (14.7%)
Cell differentiation, n (%) 0.001
Good 61 (13.2%) 40 (11.0%) 21 (21.4%)
Moderate 330 (71.6%) 259 (71.3%) 71 (72.4%)
Poor 70 (15.2%) 64 (17.6%) 6 (6.1%)
Perineural invasion, n (%) <0.001
Negative 235 (62.0%) 176 (57.5%) 59 (80.8%)
Positive 144 (38.0%) 130 (42.5%) 14 (19.2%)
Lymphovascular invasion, n (%) 0.678
Negative 254 (67.0%) 203 (66.3%) 51 (69.9%)
Positive 125 (33.0%) 103 (33.7%) 22 (30.1%)
SD, standard deviation.
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Most of the 5-year survival rates reported in the literature are
actuarial and represent estimates of 5-year survival after resec-
tion. In fact, few studies on periampullary adenocarcinomas
report actual 5-year survival figures. It has been suggested that
actuarial 5-year survival estimates may be higher than actual
5-year survival rates.13,24 The current study reports actual 5-year
survival in a large group of patients with a variety of
periampullary adenocarcinomas, which enables a subgroup
analysis. This confirms that a worse prognosis is associated with
pancreatic head adenocarcinoma compared with the other
disease subgroups. Because the numbers of patients surviving to
10 years is low, it was not possible to compare 10-year actuarial
survival among patients with pancreatic head, distal CBD and
duodenal adenocarcinomas by histological subgroup. However,
patients with ampullary adenocarcinoma who survived to 5
years were found to have a 74.4% probability of surviving to 10
years, with the most likely cause of death being the disease
process itself.
The clinicopathological characteristics contributing to long-
term survival (i.e. 5 years) remain controversial.12,13,29 Patho-
logic factors have been proposed as the most important
prognostic indicators of longterm survival, and include non-
pancreatic primary cancers, negative lymph node status, a low
number of positive lymph nodes, smaller tumour size, curative
resection, well-differentiated tumours, and no invasion of the
extrapancreatic nerve plexus.10–16,19,26,27,29,30 Surgical factors, such
as curative resection with negative margins, that lack postopera-
tive complications are independent variables that are significantly
associated with longterm survival.16,29 In the current study, many
of these factors seemed to be important on univariate analysis.
However, only primary tumour diagnosis, jaundice, intra-
abdominal abscess, tumour stage, tumour size, radicality, lymph
Table 4 Independent predictors of longterm survival [5 years after pancreaticoduodenectomy (PD)] by multivariate analysis in a binary
logistic regression model
Odds ratio 95% CI P-value
Gender 1.015 0.348–2.965 0.798
Diagnosis of primary tumour (pancreatic versus non-pancreatic) 2.318 0.541–9.935 0.002
Jaundice 0.828 0.730–0.938 0.002
Epigastric pain 1.107 0.362–3.386 0.798
Diabetes mellitus 0.967 0.871–1.072 0.545
Radiotherapy 0.734 0.214–2.516 0.403
Operation time (<7.5 h versus 7.5 h) 1.039 0.266–4.053 0.312
Blood loss (<800 ml versus 800 ml) 0.522 0.180–1.511 0.136
Pylorus-preserving PD 1.673 0.435–6.438 0.415
Post-PD bleeding 1.200 0.178–8.106 0.907
Intra-abdominal abscess 1.257 0.869–1.817 0.003
Stage (I + II versus III + IV) 1.602 0.383–6.708 0.780
Tumour size (2.0 cm versus >2.0 cm) 0.384 0.127–1.162 0.006
Radicality (curative versus palliative) 0.500 0.072–3.496 0.015
Lymph node involvement 0.339 0.096–1.196 0.021
Cell differentiation (good + moderate versus poor) 0.000 0.000–1.265 0.028
Perineural invasion 1.177 0.817–1.695 0.085
95% CI, 95% confidence interval.
Table 5 Data for 10-year survival in longterm survivors (survival 5 years) of periampullary adenocarcinomas after
pancreaticoduodenectomy
Survival, months,
median (range)
Actuarial 10-year
survival
Patients
alive, n
Periampullary adenocarcinomas (n = 109) 137.3 (60.8–341.1) 73.2% 56
Pancreatic head adenocarcinoma (n = 11) 112.5 (60.8–293.7) 49.1% 2
Ampullary adenocarcinoma (n = 83) 143.9 (62.4–341.1) 74.4% 46
Distal CBD adenocarcinoma (n = 10) 137.1 (62.0–208.1) 87.5% 7
Duodenal adenocarcinoma (n = 5) 84.4 (60.8–341.1) 50.0% 1
CBD, common bile duct.
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node status and cell differentiation remained as independent
factors associated with longterm survival. Some investigators
have reported that patients with more advanced stages of can-
cer (i.e. a large tumour size and/or lymph node metastasis) can
be cured by surgical resection.12,13 This suggests that poor prog-
nostic factors, such as large tumour size or lymph node metas-
tasis, do not necessarily preclude an actual 5-year survival, and
therefore active surgical resection with curative intent should be
attempted in all patients with resectable disease.12,13 Chemo-
therapy is currently the standard of care for pancreatic cancer.
However, only 43.2% of patients in the present study received
chemotherapy. This may partially explain why actual survival in
this study was found to be lower than actuarial survival reported
in the literature.
In summary, of patients submitted to PD, most longterm sur-
vivors are those with ampullary adenocarcinoma. Actual 5-year
survival in patients with pancreatic ductal adenocarcinoma is
6.5%. This would appear to be significantly lower than reported
actuarial 5-year survival figures. Independent factors associated
with longterm survival were primary tumour diagnosis, jaundice,
intra-abdominal abscess, tumour stage, tumour size, radicality,
lymph node status and cell differentiation.
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